If a picture is worth a thousand words, how about a Facebook video from a stem cell clinic? In my view it sure tells a story with some unusual twists. I wrote last week about this Facebook video by Kristin Comella, the leader of the publicly-traded stem cell clinic firm US Stem Cell, Inc. (USRM). As […]
Up your nose? OMG Facebook video moments from clinic sued by DOJ Read More »
There’s an idea floating around out there called “young blood” to use donations from young folks to infuse older people to reverse aging. I’m skeptical. Imagine an old man and a teenager sitting side by side, with blood flowing from the kid to the oldster in a stab at anti-aging. Sort of like a one-way
Young blood as anti-aging fountain of youth: hype or hope? Read More »
New FDA Commissioner Dr. Scott Gottlieb, M.D., has in the past touched on stem cells and regenerative medicine therapies in speeches or written comments prior to starting his tenure at the agency. Now that he is Commissioner, he is poised to have direct impact on our field rather quickly and potentially with major changes in
Reading the tea leaves as new FDA commish Gottlieb blogs on regenerative medicine Read More »
What were the top posts here on The Niche for the past year? I’ve listed some of them below along with some posts from 2015 that remain highly read. Some top 2016 posts 20 Nominees for Stem Cell Person of the Year 2016 Award REGROW Act is Attack on Science-Based Stem Cell Trial Oversight Will new
The Niche top posts of 2016 Read More »
Today an opinion piece that I wrote about CIRM was published in the San Francisco Chronicle. The unusual element here is that the article is critical of CIRM. More specifically I raised concerns about a recent political trend at CIRM under its new President Randy Mills lobbying for dramatically weaker stem cell regulatory oversight. The Chronicle piece was first posted
The backstory on my opinion piece in SF Chronicle critical of CIRM lobbying Read More »
I talked last year about human genetic modification by CRISPR with George Church a year ago. Now we’ve followed up with a long chat on this topic going into much more detail and with questions on recent developments. Each question is listed numerically and then there is a back and forth on that question with George
George Church chat: CRISPR people, Zika, weapons Read More »
There’s a growing trend whereby patients have to pay to be in a clinical trial, which are called pay-to-play clinical trials. Proponents of this idea point toward potential benefits in the form of patients gaining access to innovative therapies. They also argue that this approach provides a much-needed funding mechanism for the trials and that
Poll: How do you feel about pay-to-play clinical trials? Read More »
Discussion of concerns over heritable human genetic modification has spiked in 2015. This dialogue is a good thing, but is it in a sense too late? Are genetically modified (GM) people a foregone conclusion? Rumors are swirling that upwards of four papers reporting production of GM human embryos are in various stages of review at high-profile
Genetic Modification of Humans Now Inevitable? Read More »
The science reads on my radar screen to read in my ample spare time as I work the weekend on literally 5 different grants include these pieces: NECSS and SfSBM: A weekend of science and skepticism Breaking Down Fat: Trends in adipose cell-based clinical trials PubPeer Selections: Odd citations, “practice makes perfect,” a Nature update
Recommended Weekend Science Reads Read More »
Cloning of animals is becoming a big, global business, and Hwang Woo-Suk is a major player here. Hwang Woo-Suk and animal cloning It turns out that this reproductive cloning of animals goes well beyond making duplicates of pets for sentimental customers at $100,000 a copy. Cloning of livestock by agribusinesses is becoming fairly common. Some
Cloning Factory in China Has Familiar Partner: Hwang Woo-Suk Read More »